|
[1] BECKETT AG, LIVINGSTONE AV, HILL KR. Acute alcoholichepatitis[J]. Br Med J, 1961, 2 (5260) :1113-1139.
|
|
[2] CRABB DW, BATALLER R, CHALASANI NP, et al. Standarddefinitions and common data elements for clinical trials in pa-tients with alcoholic hepatitis:Recommendation from theNIAAA alcoholic hepatitis consortia[J]. Gastroenterology, 2016, 150 (4) :785-790.
|
|
[3] MANDREKAR P, BATALLER R, TSUKAMOTO H, et al. Alco-holic hepatitis:Translational approaches to develop targetedtherapies[J]. Hepatology, 2016, 64 (4) :1343-1355.
|
|
[4] GAO B, BATALLER R. Alcoholic liver disease:pathogenesisand new therapeutic targets[J]. Gastroenterology, 2011, 141 (5) :1572-1585.
|
|
[5] SEITZ HK, BATALLER R, CORTEZ-PINTO H, et al. Alcoholicliver disease[J]. Nat Rev Dis Primers, 2018, 4 (1) :16.
|
|
[6] XU MJ, ZHOU Z, PARKER R, et al. Targeting inflammation forthe treatment of alcoholic liver disease[J]. Pharmacol Ther, 2017, 180:77-89.
|
|
[7] CHEN P, MIYAMOTO Y, MAZAGOVA M, et al. Microbiota and al-coholic liver disease[J]. Alcohol Clin Exp Res, 2016, 40 (8) :1791-1792.
|
|
[8] DUBUQUOY L, LOUVET A, LASSAILLY G, et al. Progenitorcell expansion and impaired hepatocyte regeneration in ex-planted livers from alcoholic hepatitis[J]. Gut, 2015, 64 (12) :1949-1960.
|
|
[9] BERTOLA A, MATHEWS S, KI SH, et al. Mouse model ofchronic and binge ethanol feeding (the NIAAA model) [J].Nat Protoc, 2013, 8 (3) :627-637.
|
|
[10] LAZARO R, WU R, LEE S, et al. Osteopontin deficiency doesnot prevent but promotes alcoholic neutrophilic hepatitis inmice[J]. Hepatology, 2015, 61:129-140.
|
|
[11] BERTOLA A, PARK O, GAO B. Chronic plus binge ethanolfeeding synergistically induces neutrophil infiltration and liverinjury:A critical role for E-selectin[J]. Hepatology, 2013, 58 (5) :1814-1823.
|
|
[12] GAO B, XU MJ, BERTOLA A, et al. Animal models of alcohol-ic liver disease:Pathogenesis and clinical relevance[J].Gene Expr, 2017, 17 (3) :173-186.
|
|
[13] KI SH, PARK O, ZHENG M, et al. Interleukin-22 treatment amel-iorates alcoholic liver injury in a murine model of chronic-bingeethanol feeding:Role of signal transducer and activator of tran-scription 3[J]. Hepatology, 2010, 52 (4) :1291-1300.
|
|
[14] PETRASEK J, BALA S, CSAK T, et al. IL-1 receptor antagonistameliorates inflammasome-dependent alcoholic steatohepatitisin mice[J]. J Clin Invest, 2012, 122 (10) :3476-3489.
|
|
[15] SZABO G. Clinical trial design for alcoholic hepatitis[J]. Se-min Liver Dis, 2017, 37 (4) :332-342.
|
|
[16] SINGAL AK, SHAH VH. Therapeutic strategies for the treat-ment of alcoholic hepatitis[J]. Semin Liver Dis, 2016, 36 (1) :56-68.
|
|
[17] GAO B, XIANG X. Interleukin-22 from bench to bedside:Apromising drug for epithelial repair[J]. Cell Mol Immunol, 2018.[Epub ahead of print]
|
|
[18] SINGH V, KEISHAM A, BHALLA A, et al. Efficacy of granulo-cyte colony-stimulating factor and N-acetylcysteine thera-pies in patients with severe alcoholic hepatitis[J]. Clin Gastro-enterol Hepatol, 2018, 16 (10) :1650-1656. e2.
|
|
[19] SINGH V, SHARMA AK, NARASIMHAN RL, et al. Granulocytecolony-stimulating factor in severe alcoholic hepatitis:A ran-domized pilot study[J]. Am J Gastroenterol, 2014, 109 (9) :1417-1423.
|
|
[20] MATHURIN P, MORENO C, SAMUEL D, et al. Early livertransplantation for severe alcoholic hepatitis[J]. N Engl JMed, 2011, 365 (19) :1790-1800.
|
|
[21] ARTRU F, LOUVET A, MATHURIN P. Liver transplantation forpatients with alcoholic hepatitis[J]. Liver Int, 2017, 37 (3) :337-339.
|
|
[22] LEE BP, MEHTA N, PLATT L, et al. Outcomes of early livertransplantation for patients with severe alcoholic hepatitis[J].Gastroenterology, 2018, 155 (2) :422-430. e1.
|
|
[23] LEE BP, CHEN PH, HAUGEN C, et al. Three-year results ofa pilot program in early liver transplantation for severe alcoholichepatitis[J]. Ann Surg, 2017, 265 (1) :20-29.
|
|
[24] WU T, MORGAN TR, KLEIN AS, et al. Controversies in earlyliver transplantation for severe alcoholic hepatitis[J]. AnnHepatol, 2018, 17 (5) :759-768.
|
DownLoad: